Publications by authors named "Kostelli Gavriella"

Article Synopsis
  • The study investigates whether carotid-to-femoral pulse wave velocity (PWV), a measure of arterial stiffness, can predict cardiovascular risks beyond the SCORE2 risk score in individuals without existing atheromatosis.
  • Over a 6-year follow-up of 747 participants, results show that higher PWV is an independent predictor of first cardiovascular events (like strokes and heart attacks) and enhances the predictive power of SCORE2.
  • The findings suggest that including PWV in risk assessments may significantly improve the identification of individuals at risk for major adverse cardiovascular events (MACE), validating its importance in cardiovascular health monitoring.
View Article and Find Full Text PDF

Psoriasis predisposes to cardiovascular dysfunction. We investigated whether glycocalyx dietary supplement (GDS), which contains glycosaminoglycans and fucoidan, improves endothelial glycocalyx and arterial stiffness in psoriatic patients. Fifty participants with psoriasis under biological agents were randomly assigned to GDS (n = 25) or placebo (n = 25) for 4 months.

View Article and Find Full Text PDF

: Glucagon-like peptide-1 receptor agonists (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT-2i) are cardioprotective drugs. We investigated their effects on left atrial function, a major determinant of cardiac diastolic dysfunction in type 2 diabetes mellitus. We also explored the association of changes in arterial stiffness with those of the LA strain after treatment.

View Article and Find Full Text PDF

Endothelial glycocalyx (EG) derangement has been associated with cardiovascular disease (CVD). Studies on EG integrity among people living with HIV (PLWH), are lacking. We conducted a prospective cohort study among treatment-naïve PLWH who received emtricitabine/tenofovir alafenamide, combined with either an integrase strand transfer inhibitor (INSTI, dolutegravir, raltegravir or elvitegravir/cobicistat), or a protease inhibitor (PI, darunavir/cobicistat).

View Article and Find Full Text PDF

Aims: Psoriasis has been associated with increased cardiovascular (CV) risk. We investigated whether markers of CV function and their change after treatment have a prognostic value for adverse outcomes.

Methods And Results: In a prospective study, at baseline and after 6 months of treatment with biological agents, we assessed in 298 psoriasis patients (i) left ventricular global longitudinal strain (GLS) and (ii) carotid-femoral pulse wave velocity (PWV), to evaluate their prognostic value for major adverse cardiovascular events (MACEs), including coronary artery disease, stroke, hospitalization for heart failure, and all-cause death over a 4-year follow-up period.

View Article and Find Full Text PDF

Background: Fagerstrom score is a validated marker of nicotine addiction in smokers.

Methods: In a prospective study, we investigated a) the predictive value of Fagerstrom score for the smoking status in patients early after acute myocardial infarction (AMI) and b) the effectiveness of medically assisted smoking cessation programs in the prevention of relapsing to smoking post discharge. In 103 smokers (58 ± 12 years, 79.

View Article and Find Full Text PDF

The phosphodiesterase 4 inhibitor apremilast is used for the treatment of psoriasis. We investigated the effects of apremilast on endothelial glycocalyx, vascular and left ventricular (LV) myocardial function in psoriasis. One hundred and fifty psoriatic patients were randomized to apremilast ( = 50), anti-tumor necrosis factor-α (etanercept; = 50), or cyclosporine ( = 50).

View Article and Find Full Text PDF

Psoriatic disease is associated with vascular and myocardial dysfunction. We aimed to evaluate endothelial glycocalyx barrier properties and microvascular perfusion in psoriatic patients, as well as their correlation with carotid intima-media thickness (cIMT) and markers of left ventricular (LV) myocardial deformation. We examined 297 psoriatic patients and 150 controls, adjusted for age, sex, and atherosclerotic risk factors.

View Article and Find Full Text PDF

We investigated whether disturbance of glycocalyx integrity is related with increased cardiovascular risk. In 600 healthy subjects, we measured perfused boundary region (PBR), a marker of glycocalyx integrity, in sublingual microvessels with diameter ranging 5-25 µm using a dedicated camera (Sideview Darkfield Imaging). Increased PBR indicates reduced glycocalyx thickness.

View Article and Find Full Text PDF
Article Synopsis
  • Turner syndrome (TS) is linked to higher cardiovascular risks, and a study examined the effects of hormone replacement therapy (HRT) on cardiovascular measures in women with TS.
  • The study involved 25 women with TS undergoing various tests during HRT and two months after stopping it, comparing their results to healthy controls.
  • Findings showed that while on HRT, women with TS had worse endothelial function and increased arterial stiffness; however, two months after stopping HRT, their endothelial function improved and arterial stiffness decreased.
View Article and Find Full Text PDF

We examined the effects of electronic cigarette on platelet and vascular function after 4 months of use compared to tobacco smoking. Forty smokers without cardiovascular disease were randomized to smoke either conventional cigarettes or an electronic cigarette (nicotine concentration of 12 mg/ml). At baseline and after four months, we measured a) platelet function by Platelet Function Analyzer PFA-100 and Light Transmission Aggregometry, b) pulse wave velocity, c) plasma malondialdehyde levels as oxidative stress index and d) the exhaled CO level.

View Article and Find Full Text PDF

Background: Anakinra, an interleukin-1 receptor antagonist and tocilizumab, an interleukin-6 receptor blocker, are used for the treatment of rheumatoid arthritis. We investigated the differential effects of anakinra and tocilizumab on myocardial and vascular function in an atherosclerosis model of patients with rheumatoid arthritis.

Methods: 120 patients with rheumatoid arthritis were randomized to anakinra (n = 40), tocilizumab (n = 40) or prednisolone (n = 40) for 3 months.

View Article and Find Full Text PDF